Philip Tracy

704 total citations · 1 hit paper
7 papers, 534 citations indexed

About

Philip Tracy is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Philip Tracy has authored 7 papers receiving a total of 534 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 4 papers in Oncology and 2 papers in Molecular Biology. Recurrent topics in Philip Tracy's work include Lung Cancer Treatments and Mutations (3 papers), Colorectal Cancer Treatments and Studies (2 papers) and HER2/EGFR in Cancer Research (2 papers). Philip Tracy is often cited by papers focused on Lung Cancer Treatments and Mutations (3 papers), Colorectal Cancer Treatments and Studies (2 papers) and HER2/EGFR in Cancer Research (2 papers). Philip Tracy collaborates with scholars based in United States and Italy. Philip Tracy's co-authors include Nora Feeney, Cloud P. Paweletz, Pasi A. Jänne, Geoffrey R. Oxnard, Kenneth S. Thress, Yuebi Hu, Kathryn F. Mileham, Lynette M. Sholl, Suzanne E. Dahlberg and Amanda J. Redig and has published in prestigious journals such as Blood, Cancer Research and Journal of Thoracic Oncology.

In The Last Decade

Philip Tracy

5 papers receiving 530 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

2018 513 citations Geoffrey R. Oxnard, Yuebi Hu et al. JAMA Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Philip Tracy United States	4	472	354	211	168	41	7	534
Tzu‐Hsiu Tsai Taiwan	13	471 1.0×	372 1.1×	183 0.9×	178 1.1×	48 1.2×	17	611
C. Zhou China	9	551 1.2×	449 1.3×	202 1.0×	153 0.9×	47 1.1×	50	660
K. Park South Korea	8	636 1.3×	529 1.5×	219 1.0×	123 0.7×	36 0.9×	25	714
Eamon M. Berge United States	8	425 0.9×	303 0.9×	231 1.1×	141 0.8×	41 1.0×	14	540
Chiara Bennati Italy	13	502 1.1×	406 1.1×	180 0.9×	158 0.9×	72 1.8×	40	632
Masaru Jida Japan	7	271 0.6×	251 0.7×	272 1.3×	105 0.6×	34 0.8×	14	469
Ichiro Nakachi Japan	13	374 0.8×	263 0.7×	269 1.3×	138 0.8×	23 0.6×	34	629
Kosei Tajima Japan	8	611 1.3×	529 1.5×	150 0.7×	98 0.6×	24 0.6×	15	706
Antonella Flacco Italy	9	482 1.0×	381 1.1×	269 1.3×	179 1.1×	67 1.6×	13	623
Anna Squadrilli Italy	11	394 0.8×	392 1.1×	220 1.0×	127 0.8×	37 0.9×	17	560

Countries citing papers authored by Philip Tracy

Since Specialization

Citations

This map shows the geographic impact of Philip Tracy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip Tracy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip Tracy more than expected).

Fields of papers citing papers by Philip Tracy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip Tracy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip Tracy. The network helps show where Philip Tracy may publish in the future.

Co-authorship network of co-authors of Philip Tracy

This figure shows the co-authorship network connecting the top 25 collaborators of Philip Tracy. A scholar is included among the top collaborators of Philip Tracy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip Tracy. Philip Tracy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Tracy, Philip, Ana C. Garrido-Castro, Antonio Giordano, et al.. (2025). Management of Metastatic Hormone Receptor-Positive Breast Cancer Beyond CDK4/6 Inhibitors. Current Oncology Reports. 27(7). 915–933.

2.

Tracy, Philip, et al.. (2022). Systematic Review and Network Meta-Analysis of Frontline Targeted Therapy in Chronic Lymphocytic Leukemia Shows Comparable Efficacy but Distinct Toxicity. Blood. 140(Supplement 1). 12423–12424. 1 indexed citations

3.

Tracy, Philip, et al.. (2021). Pulmonary Tumor Thrombotic Microangiopathy as a Cause of Pulmonary Hypertension. JACC Case Reports. 3(7). 1029–1031. 4 indexed citations

4.

Tracy, Philip, et al.. (2021). Risk Factors for Early Sudden Cardiac Death in Patients with Systemic Light-Chain Amyloidosis on Treatment. Blood. 138(Supplement 1). 3756–3756.

5.

Oxnard, Geoffrey R., Yuebi Hu, Kathryn F. Mileham, et al.. (2018). Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncology. 4(11). 1527–1527. 513 indexed citations breakdown →

6.

Oxnard, Geoffrey R., Yuebi Hu, Kathryn F. Mileham, et al.. (2017). OA 09.02 Osimertinib Resistance Mediated by Loss of EGFR T790M Is Associated with Early Resistance and Competing Resistance Mechanisms. Journal of Thoracic Oncology. 12(11). S1767–S1768. 13 indexed citations

7.

Oxnard, Geoffrey R., Yuebi Hu, Philip Tracy, et al.. (2017). Abstract 4112: Overgrowth of competing resistance mechanisms, such as an acquired KRAS mutation, underlies a poor prognosis subtype of acquired resistance to osimertinib in T790M-positive NSCLC. Cancer Research. 77(13_Supplement). 4112–4112. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact